The Rani platform is capable of delivering orally any payload, including proteins, peptides, and antibodies, to which could help millions of patients fight their disease in a wide range of …

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the …

6 days ago · Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs.

Rani is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to …

RT-105 is the original RaniPill capsule containing a TNF-α inhibitor antibody for the treatment of psoriatic arthritis. Several TNF-alpha antibodies, such as adalimumab, have been approved by …

6 days ago · Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has …

Rani Therapeutics has developed a disruptive technology for the oral delivery of biologics. The RaniPill® Capsule is an innovative robotic pill that moves fully intact through the stomach, …

Rani Therapeutics also announced its anticipation for a Phase 1 clinical trial in 2025 for RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, developed in partnership with ProGen.

SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on …

Jun 24, 2024 · Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous …